OTR-AC vs Thymosin Beta-4 — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
OTR-AC is the common name for oral high-dose BPC-157 acetate. The peptide sequence (GEPPPGKPADDAGLV) is identical to injectable BPC-157 but is dosed at 2–5 mg orally rather than 250–500 µg subcutaneously to compensate for GI degradation and first-pass metabolism. The oral route p...
Calculate OTR-AC dose →Thymosin Beta-4 (TB-4) is the full-length 43-amino acid actin-sequestering peptide from which the commonly used research fragment TB-500 (residues 17-23, LKKTETQ) is derived. TB-4 is the most abundant thymosin-family protein in virtually all mammalian cells, where it maintains th...
Calculate Thymosin Beta-4 dose →| Parameter | OTR-AC | Thymosin Beta-4 |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Research | Preclinical | Extensively Studied |
| Half-Life | 4–6 hours (estimated, oral) | ~30-60 min (plasma) |
| Typical Dose | 2–5 mg | 1.5-2.5 mg, 2-3x/week |
| Frequency | Once daily | 2-3 times per week |
| Route | Oral | Subcutaneous, IV, Topical, Intranasal |
| FDA Status | Not Approved | Phase II |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.